Clinical Trial Update: Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is assessing furmonertinib in combination with intrathecal chemotherapy and stereotactic radiotherapy for EGFR-mutated non-small cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Leptomeningeal Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: RECRUITING